Filing Flows › RxSight (RXST) › Q3 2026 › vs Q3 2025
RxSight (RXST) Q3 2026 vs Q3 2025 (year over year)
RxSight's revenue fell $5.8M (-19%) from $30.3M in Q3 2025 to $24.6M in Q3 2026. The biggest changes: Rxlal −$2.9M (-11%); LDD −$2.7M (-87%); Service Warranty Service Contracts and Accessories −$122K (-8%).
RxSight, Q3 2026: revenue $24.6M (-19% year over year), operating margin -75.3%, net loss $16.2M, operating cash flow $45.2M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 179.1% | -5.8% | +185.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Rxlal | $22.8M | $25.7M | −$2.9M | -11% |
| Service Warranty Service Contracts and Accessories | $1.4M | $1.5M | −$122K | -8% |
| LDD | $427K | $3.2M | −$2.7M | -87% |
| Revenue | $24.6M | $30.3M | −$5.8M | -19% |
| Other income, net | $2.3M | $2.4M | −$50K | -2% |
| Net loss | $16.2M | $9.8M | $6.4M | +65% |
| Costs & expenses | $43.1M | $42.5M | $605K | +1% |
| Operating costs | $43.1M | $42.5M | $586K | +1% |
| Income tax | $28K | $10K | $18K | +180% |
| Research & development | $9.2M | $9.1M | $153K | +2% |
| SG&A | $27.4M | $27.3M | $59K | +0.2% |
| Operating cash sources | $61.4M | $8.6M | $52.8M | +612% |
| Depreciation & amortization | $929K | $854K | $75K | +9% |
| Share-based compensation | $7.6M | $8.1M | −$474K | -6% |
| Working capital & other | $52.9M | −$333K | $53.2M | — |
| Net loss absorbed | $16.2M | $9.8M | $6.4M | +65% |
| Operating cash flow | $45.2M | −$1.2M | $46.4M | — |
| Free cash flow (OCF − capex) | $44.0M | −$1.8M | $45.8M | — |
| Capital expenditures | $1.2M | $581K | $593K | +102% |
Questions
How much did RxSight's revenue grow year over year in Q3 2026?
RxSight's revenue fell $5.8M (-19%) from $30.3M in Q3 2025 to $24.6M in Q3 2026.
What drove RxSight's revenue change in Q3 2026?
Rxlal −$2.9M (-11%); LDD −$2.7M (-87%); Service Warranty Service Contracts and Accessories −$122K (-8%).